ClinicalTrials.gg
CompletedNCT01034306Updated May 24, 2022Results posted

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of CF101 and Placebo control in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Arthritis, Rheumatoid with a site in Bulgaria — 3 open to participants now, 7 under way, 1 of them phase 3. Arthritis, Rheumatoid · Bulgaria.

Enrollment
123rd of 136
79 · median 398
Started
2010
with 7 others
Phase 2
65 of 139
3 open now
Registered
31st of 139
by date

Among the 139 studies in Arthritis, Rheumatoid with a site in Bulgaria, this one is the 123rd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2010, is one of 65 in phase 2, and was the 31st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 139 studies in Arthritis, Rheumatoid with a site in Bulgaria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Arthritis, Rheumatoid with a site in Bulgaria, or all of them as a file.
02

Study summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.

Read the detailed description

This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, study in which patients with active RA and high A3AR expression at baseline will be randomized to the addition of either CF101 1.0 mg or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ages 18-75 years
  • Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324, Appendix 1)
  • Not bed- or wheelchair-bound
  • Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the for the central reference laboratory
  • Elevated PBMC A3AR expression level, defined as >= 1.5-fold over a predetermined normal population standard, following the appropriate DMARD/biologic (see Exclusion Criteria) but within 2 weeks of beginning dosing
  • If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to the A3AR Qualification Visit, and will remain unchanged during protocol participation
  • If taking an oral , dose is \<=10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the A3AR Qualification Visit, and will remain unchanged during protocol participation
  • In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  • Negative screening serum pregnancy test for female patients of
  • Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)
  • All aspects of the protocol explained and written obtained

Exclusion criteria

Exclusion Criteria:

  • Receipt of any of the following for at least a 1 month prior to the A3AR Qualification Visit: methotrexate, sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra
  • Receipt of etanercept for at least a 6 week washout period prior to the A3AR Qualification Visit
  • Receipt of chloroquine, hydroxychloroquine, cyclosporine, infliximab, golimumab or adalimumab for at least a 2 month washout period prior to the A3AR Qualification Visit
  • Receipt of leflunomide for at least a 2 month washout period prior to the A3AR Qualification Visit, unless patient has undergone cholestyramine washout at least 1 month prior to testing
  • Receipt of cyclophosphamide for at least a 6 month period prior to the A3AR Qualification Visit
  • Receipt of rituximab at any previous time
  • Previous failure to respond to methotrexate or any anti-rheumatic biological agent
  • Participation in a previous trial CF101 trial
  • Use of oral >10 mg of prednisone, or equivalent, per day
  • Change in NSAID dose level for 1 month prior to the A3AR Qualification Visit
  • Change in oral corticosteroid dose level during the 1 month prior to the A3AR Qualification Visit
  • Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to the A3AR Qualification Visit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    CF101 1 mg

    piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks

    Drug: CF101

  • Placebo comparator
    Placebo

    placebo tablet to match the active, oral dosage, Q12h for 12 weeks

    Drug: Placebo control

Interventions

  • DrugCF101

    orally q12h

    Also known as: IB-MECA

  • DrugPlacebo control

    orally q12 hours

    Also known as: Inactive pill

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)

    ACR20 Response is defined as a 20% improvement from baseline in disease: 1. \>20% improvement in tender joint count (TJC), and 2. \>20% improvement in swollen joint count (SJC), and 3. \>20% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Subjects Achieving an ACR50 Response (50% Improvement)

    ACR50 Response is defined as a 50% improvement from baseline in disease: 1. \>50% improvement in TJC, and 2. \>50% improvement in SJC, and 3. \>50% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

    Time frame: 12 weeks

  2. Number of Subjects Achieving an ACR70 Response (70% Improvement)

    ACR70 Response is defined as a 70% improvement from baseline in disease: 1. \>70% improvement in TJC, and 2. \>70% improvement in SJC, and 3. \>70% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

    Time frame: 12 weeks

07

Results

Posted Mar 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneCF101 1mgPlacebo
Started4237
Completed3734
Not completed53
Withdrew: Adverse event10
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject22
Withdrew: Hospitalized and decided to stop10
Withdrew: Noncomplience10

Outcome measures

PrimaryNumber of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)

ACR20 Response is defined as a 20% improvement from baseline in disease: 1. \>20% improvement in tender joint count (TJC), and 2. \>20% improvement in swollen joint count (SJC), and 3. \>20% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)
ParticipantsCF101 1mgPlacebo
Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)188
Statistical analysis
  • CF101 1mg vs Placebo · t-test, 2 sided · p = 0.0352 (normal approximation to the binomial test)
SecondaryNumber of Subjects Achieving an ACR50 Response (50% Improvement)

ACR50 Response is defined as a 50% improvement from baseline in disease: 1. \>50% improvement in TJC, and 2. \>50% improvement in SJC, and 3. \>50% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving an ACR50 Response (50% Improvement)
ParticipantsCF101 1mgPlacebo
Number of Subjects Achieving an ACR50 Response (50% Improvement)73
Statistical analysis
  • CF101 1mg vs Placebo · t-test, 2 sided · p = .2472
SecondaryNumber of Subjects Achieving an ACR70 Response (70% Improvement)

ACR70 Response is defined as a 70% improvement from baseline in disease: 1. \>70% improvement in TJC, and 2. \>70% improvement in SJC, and 3. \>70% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving an ACR70 Response (70% Improvement)
ParticipantsCF101 1mgPlacebo
Number of Subjects Achieving an ACR70 Response (70% Improvement)41
Statistical analysis
  • CF101 1mg vs Placebo · t-test, 2 sided · p = 0.1972

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 1mg—1/42 (2.4%)0/42 (0%)
Placebo—1/37 (2.7%)0/37 (0%)
Most frequent serious events
Most frequent serious events
EventCF101 1mgPlacebo
atrial fibrillation with uncontrolled ventricular responseCardiac disorders0/421/37
PyodermaInfections and infestations1/420/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)CF101 1mgPlaceboTotal
Mean56.7 ± 9.8761.7 ± 6.8959 ± 8.92
Sex: Female, Male
Sex: Female, Male(Participants)CF101 1mgPlaceboTotal
Female323264
Male10515
08

Study locations

5 sites
  • Multiprofile Hospital for Active Treatment
    Sofia, 1359, Bulgaria
  • Diagnostic Consultative Center Sofia
    Sofia, 1505, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • UMHAT "Sveti Ivan Rilski", Rheumatoloty Clinic
    Sofia, 1612, Bulgaria
  • Barzilai Medical Center
    Ashkelon, Israel
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2009
First posted
Dec 17, 2009
Start
Oct 2010
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Mar 9, 2015
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01034306
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Dec 17, 2009
Start date
Oct 2010
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Mar 9, 2015
Last update
May 24, 2022

Study contacts

Michael H Silverman, MD
study director · BioStrategics Consulting Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion